Primary brain lymphoma cell turnover differs in patients with and without AIDS: Relationships to bcl-2 expression and host cell reaction

Journal of Neuropathology and Experimental Neurology

Volumn 58, Issue 10, 1999, Pages 1069-1077

  Christov, C ^a,b   Adle Biassette, H ^a,b   Lechapt, E ^a,b   Poron, F ^b   Gray, F ^c   Gaulard, P ^a   Gherardi, R K ^a,b  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c RAYMOND POINCARÉ HOSPITAL   (France)

Author keywords

AIDS; Apoptosis; Cell turnover; Primary brain lymphomas; Proliferation; Tumor infiltrating T lymphocytes

Indexed keywords

PROTEIN BCL 2;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; APOPTOSIS; ARTICLE; BRAIN LYMPHOMA; CELL KINETICS; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MACROPHAGE; MITOSIS INDEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0032882690     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005072-199910000-00005     Document Type: Article

References (68)

1. Fine HA, Mayer RJ. Primary central nervous system lymphoma. Ann Intern Med 1993;119:1093-104
2. Paulus W, Jellinger K, Morgello S. Malignant lymphomas. In: Kleihues P, Cavanee W, eds. Pathology & genetics, tumours of the central nervous system. Lyon: International Agency for Research on Cancer, 1997:154-69
3. De Angelis LM. Current management of primary central nervous system lymphoma. Oncology 1995;9:63-71
4. Forsyth PA, Yahalom J, De Angelis LM. Combined-modality therapy in the treatment of primary central nervous system lymphoma in AIDS. Neurology 1994;44:1473-79
5. Kaufmann T, Nisce LZ, Coleman M. A comparison of survival of patients treated for AIDS-related central nervous system lymphoma with and without tissue diagnosis. Int J Radiat Oncol Biol Phys 1996;36:429-32
6. Levine AM. Acquired immunodeficiency syndrome-related lymphoma Blood 1992;80:8-20
7. Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin's lymphoma of the brain: Can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the radiation Therapy Oncology Group (RTOG):RTOG 8315. Int J Radiat Oncol Biol Phys 1992;23:9-17
8. Chamberlain MC. Long survival in patients with acquired immune deficiency syndrome-related primary central nervous system lymphoma. Cancer 1994;73:1728-30
9. Bessell EM, Punt J, Firth J, Hope T, Holland I, Lowe J. Primary non-Hodgkin's lymphoma of the central nervous system: Phase II study of chemotherapy (BVAM) prior to radiotherapy. Clin Oncol (R Coll Radiol) 1991;3:193-98
10. O'Brien PC, Roos DE, Liew KH, et al. Preliminary results of combined chemotherapy and radiotherapy for non-AIDS primary central nervous system lymphoma. Trans-Tasman Radiation Oncology Group (TROG). Med J Aust 1996;165:424-27
11. Spina D, Leoncini L, Del Vecchio M, et al. Low versus high cell turover in diffusely growing non-Hodgkin's lymphomas [abstract]. J Pathol 1996;180:354
12. Wilson WH, Teruya-Feldstein J, Fest T, et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 1997;89:601-9
13. Winter JN, Andersen J, Reed JC, et al. bcl-2 expression correlates with lower proliferative activity in the intermediate- and high-grade non-Hodgkin's lymphomas: An Eastern Cooperative Oncology Group and Southwest Oncology Group cooperative laboratory study. Blood 1998;91:1391-98
14. Kenney JL, Guinness ME, Curiel T, Lacy J. Antisense to the Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) suppresses LMP-1 and bcl-2 expression and promotes apoptosis in EBV-immortalized B cells. Blood 1998,92:1721-27
15. Liebowitz D. Epstein-Barr virus and a cellular signalling pathway in lymphomas from immunosuppressed patients N Engl J Med 1998;338:1413-21
16. Uhr JW, Scheuermann RH, Street NE, Vitetta ES. Cancer dormancy: Opportunities and new therapeutic approaches. Nature Medecine 1997;3:505-9
17. Lee PP, Zeng D, McCanlay AE et al. T helper 2-dominant antilymphoma immune response is associated with fatal outcome. Blood 1997;90:1611-17
18. French M, Magaud JP, Ffrench P, et al. Heterogeneity of neoplastic and reactive cell proliferation in non-Hodgkin's lymphomas linked to patient survival. Am J Clin Pathol 1994;101:413-20
19. Medeiros LJ, Picker LJ, Gelb AB, et al. Number of host "helper" T cells and proliferating cells predict survival in diffuse small cell lymphomas. J Clin Oncol 1989;7:1009-17
20. Porwit-Ksiazek A, Christensson B, Lindemalm C, et al. Characterization of malignant and non-neoplastic cell phenotypes in highly malignant non-Hodgkin's lymphomas Int J Cancer 1983;32:667-74
21. Lippman SM, Spier CM, Miller TP, et al Tumor-infiltrating T-lymphocytes in B-cell diffuse large cell lymphoma related to disease outcome. Mod Pathol 1990;3:361-67
22. List AF, Spier CM, Miller TP, Grogan TM. Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma:relationship to HLA expression and host immunocompetence. Leukemia 1993;7:398-403
23. Bashir R, Chamberlain M, Ruby E, Hochberg FH. T-cell infiltration of primary CNS lymphoma. Neurology 1996;46:440-44
24. Harris NL, Jaffe AS, Stein H, et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92
25. Larocca LM, Capello D, Rinelli A, et al. The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. Blood 1998;92:1011-19
26. Hamilton-Dutoit SJ, Rea D, Raphael M, et al. Epstein-Barr viruslatent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency. Am J Pathol 1993;143:1072-85
27. Raphael M, Gentilhomme O, Tulliez M, et al. Histopathologic featyres of high-grade non-Hodgkin's lymphomas in acquired immunodeficiency syndrome. Arch Pathol Lab Med 1991;115:15-20
28. Kurtin PJ, Roche PC. Immunoperoxidase staining of non-Hodgkin's lymphomas for T-cell associated antigens in paraffin sections. Am J Surg Pathol 1993;17:898-904
29. Lan HY, Mu W, Nikolic-Paterson DJ, Atkins RC. A novel, simple, reliable, and sensitive method for multiple immunoenzyme staining: Use of microwave oven heating to block antibody cross-reactivity and retrieve antigens. J Histochem Cytochem 1995;43:97-102
30. Spina D, Leoncini L, Del Vecchio M, et al. Low versus high cell turover in diffusely growing non-Hodgkin's lymphomas. J Pathol 1995;177:335-41
31. Spina D, Leoncini L, Megha T, et al. Cellular kinetic and phenotypic heterogeneity in and among Burkitt's and Burkitt-like lymphomas. J Pathol 1997;182:145-50
32. Staunton MJ, Gaffney EF. Tumor type is a determinant of susceptibility to apoptosis. Am J Clin Pathol 1995;103:300-307
33. van Diest PJ, Brugal G, Baak JPA. Proliferation markers in tumours: Interpretation and clinical value. J Clin Pathol 1998;51: 716-24
34. Adle-Biassette H, Bell JE, Creange A, et al. DNA breaks detected by in situ end-labelling in dorsal root ganglia of patients with AIDS. Neuropathol Appl Neurobiol 1998;24:373-80
35. Abend M, Shmelz H-U, Kraft K, et al. Intercomparison of apoptosis morphology with active DNA cleavage on single cells in vitro and on testis tumours. J Pathol 1998;185:419-26
36. Camilleri-Bröet S, Davi F, Feuillard J, et al. High expression of latent membrane protein 1 of Epstein-Barr virus and bcl-2 oncoprotein in acquired immunodeficiency syndrome-related primary brain lymphomas. Blood 1995;86:432-35
37. Boulland M-L, Meignin V, Leroy-Viard K, et al. Human interleukin-10 expression in T/natural killer-cell lymphomas. Am J Pathol 1998;153:1229-37
38. Kanavaros P, Lescs M-C, Briere J, et al. Nasal T-cell lymphoma: A clinicopathologic entity associated with peculiar phenotype and Epstein-Barr virus. Blood 1993;81:2688-95
39. Gloghini A, De Paoli P, Gaidano G, et al. High frequency of CD45RO expression in AIDS-related B-cell non-Hodgkin's lymphomas Am J Clin Pathol 1995;104:680-88
40. Ameisen JC. Programmed cell death (apoptosis) and cell survival regulation: Relevance to AIDS and cancer. AIDS 1994;9:1197-213
41. Tirelli U, Errante D, Carbone A, Gloghini A, Vaccher E. Malignant lymphoma in patients with HIV-infection. Leuk Lymphoma 1996;22:245-57
42. Bergmann M, Blasius S, Bankfalvi A, Mellin W. Primary non-Hodgkin's lymphoma of the CNS - Proliferation, oncoproteins and Epstein-Barr-virus. Gen Diagn Pathol 1995/96;141:235-42
43. Camilleri-Bröet S, Davi F, Feuillard J, et al. AIDS-related primary brain lymphomas: Histopathologic and immunohistochemical study of 51 cases Hum Pathol 1997;28:367-74
44. Cobbers JM, Wolter M, Reifenberger J, et al. Frequent inactivation of CDKN2A and rare mutations of TP53 in PCNSL. Brain Pathol 1998;8:263-76
45. Krogh-Jensen M, Johansen P, D'Amore F. Primary central nervous system lymphomas in immunocompetent individuals: Histology, Epstein-Barr virus genome, Ki-67 proliferation index, p53 and bcl-2 gene expression. Leuk Lymphoma 1998;30:131-42
46. Leoncini L, Del Vecchio MT, Spina D, et al. Presence of the bcl-2 protein and apoptosis in non-Hodgkin lymphomas with diffuse growth pattern. Int J Cancer 1995;61:826-31
47. Takano Y, Saegusa M, Ikenaga M, Okayasu I. Apoptosis and proliferative activity of non-Hodgkin's lymphomas: Comparison with expression of bcl-2, p53, and c-myc proteins. Pathol Int 1997;47: 90-94
48. Deckert-Schlüter M, Rang A, Wiestler OD. Apoptosis and apoptosis-related gene products in primary non-Hodgkin's lymphoma of the central nervous system. Acta Neuropathol 1998;96:157-62
49. Labat-Moleur F, Guillermet C, Lorimer P, et al. TUNEL apoptotic cell detection in tissue sections: Critical evaluation and improvement. J Histochem Cytochem 1998;46:327-34
50. Grossman Z, Herberman RB. HIV homeostasis in HIV infection is neither failing nor blind:modified cell counts reflect an adaptive response. Nature Med 1997;3:486-90
51. Herbst H, Samol J, Foss H-D, Raff T, Niedobietek G. Modulation of interleukin-6 expression in Hodgkin and Reed-Sternberg cells by Epstein-Barr virus. J Pathol 1997;182:299-306
52. Nakagomi H, Dolcetti R, Bejarano MT, Pisa P, Kiessling R, Masucci MG. The Epstein-Barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in Burkitt lymphoma lines. Int J Cancer 1994;57:240-44
53. Aho R, Haapasalo H, Allanen K et al. Proliferative activity and DNA index do not sifnificantly predict survival in primary central nervous lymphoma. J Neuropathol Exp Neurol 1995;54:826-32
54. Hamann D, Baars PA, Rep MH, et al. Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med 1997;186:1407-18
55. Bonnefoix T, Gresson R, Jacrot M, et al. Growth modulation of freshly isolated non-Hodgkin's B-lymphoma cells induced by various cytokines and all-trans retinoic acid. Leuk Lymphoma 1997;25:169-78
56. Demanet C, Brissinck J, Leo O, et al. Role of T-cell subsets in the bispecific antibody (anti-idiotype × anti-CD3) treatment of the BCL1 lymphoma. Cancer Res 1994;54:2973-78
57. Macon WR, Cousar JB, Waldron JA, Hsu SM. Interleukin-4 may contribute to the abundant T-cell reaction and paucity of neoplastic B-cells in T-cell-rich B-cell lymphomas. Am J Pathol 1992;141: 1031-36
58. Nowell PC, Moore JS. Aberrant responses of human lymphocyte neoplasms to cytokine regulation. Immunol Res 1998;17:171-77
59. Quian JH, Titus JA, Andrew SM, et al. Human peripheral blood lymphocytes targeted with bispecific antibodies release cytokines that are essential for inhibiting tumor growth. J Immunol 1991;146: 3250-56
60. Schwartzentruber DJ, Stetler-Stevenson M, Rosenberg SA, Topalian SL. Tumor-infiltrating lymphocytes derived from select B-cell lymphomas secrete granulocyte-macrophage colony stimulating factor and tumor necrosis factor-α in response to autologous tumor stimulation. Blood 1993;82:1204-11
61. Wang J, Isaacson PG, Spencer J. Immunohistochemical analysis of T-cell proliferation in normal tonsil and B-cell lymphoma. J Clin Pathol 1995;48:873-75
62. Dorfman DM, Schulze JL, Shahsafaei A, et al. In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation. Blood 1998;90:4297-306
63. Jacob M-C, Piccinni MP, Bonnefoix T, et al. T lymphocytes from invaded lymph nodes in patients with B-cell-derived non-Hodgkin's lymphoma: Reactivity towards the malignant clone. Blood 1990;75: 1154-62
64. Greiner A, Knorr C, Qin Y et al. Low-grade B-cell lymphomas of mucosa-associated lymphoid tissue (MALT-type) require CD-40 mediated signaling and Th2-type cytokines for in vitro growth and differentiation. Am J Pathol 1997;150:1583-93
65. Koulis A, Diss T, Isaacson PG, Dogan A. Characterization of tumorinfiltrating T lymphocytes in B-cell lymphomas of mucosa-associated lymphoid tissue. Am J Pathol 1997;51:1353-60
66. Snow EC, Pittner B, Reid S. T helper cell regulation of normal and neoplastic B cell growth. Semin Immunol 1994;6:311-26
67. Diaz JI, Muro-Cacho CA. Macrophage expression of interleukin-1 in lymphoepithelioid cell ("Lennert's") lymphoma. Leuk Lymphoma 1996;21:305-9
68. Hermann M, Niemitz C, Marafioti T, Schriever F. Reduced phagocytosis of apoptotic cells in malignant lymphoma. Int J Cancer 1998;75:675-79